Iranian Journal of Child Neurology

Vol. 20 No. 3 (2026)

Successful Treatment of Refractory Landau–Kleffner Syndrome with Memantine in a Child with GRIN2A Gain-of-Function Variant

Iranian Journal of Child Neurology, Vol. 20 No. 3 (2026), 1 June 2026 , Page 87-93
https://doi.org/10.22037/ijcn.v20i3.51527

Abstract

Landau-Kleffner syndrome and related epilepsy-aphasia spectrum disorders are characterized by childhood-onset language regression, sleep-activated epileptiform activity, and frequently refractory seizures. This case report describe a boy with normal early development who developed progressive aphasia and non-motor seizures around age three, with electroencephalographic findings consistent with spike-wave activation during slow sleep, while neuroimaging and metabolic evaluations were normal. Standard antiseizure medications and repeated immunotherapy provided no sustained benefit. Genetic testing at age 12 identified a pathogenic heterozygous GRIN2A gain-of-function missense variant (p.T531M), guiding initiation of targeted therapy with memantine, and an NMDA receptor antagonist. Following memantine treatment, the patient showed marked improvement in speech and social interaction together with reduced sleep-related epileptiform discharges, although some deficits persisted. This case underscores the value of early genetic evaluation in refractory epilepsy-aphasia syndromes and supports the potential role of precision NMDA-modulating therapy in GRIN2A-associated epileptic encephalopathy.

 

Keywords:
  • Landau-Kleffner syndrome
  • GRIN2A mutation
  • Memantine

How to Cite

Mohammadi, M., Badv, R. S., Rezaei, Z., Zangooie, A., Asgari, R., & Mashayekhi, N. (2026). Successful Treatment of Refractory Landau–Kleffner Syndrome with Memantine in a Child with GRIN2A Gain-of-Function Variant. Iranian Journal of Child Neurology, 20(3), 87–93. https://doi.org/10.22037/ijcn.v20i3.51527

References

1. Muzio MR, Cascella M, Al Khalili Y. Landau Kleffner Syndrome. 2019.

2. Lesca G, Møller RS, Rudolf G, Hirsch E, Hjalgrim H, Szepetowski P. Update on the genetics of the epilepsy-aphasia spectrum and role of GRIN2A mutations. Epileptic Disord. 2019;21(S1):41–7.

3. Strehlow V, Heyne HO, Vlaskamp DRM, Marwick KFM, Rudolf G, de Bellescize J, et al. GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain. 2019;142(1):80–92.

4. Ngoh A, Clark M, Greenaway R, Chen X, Reid KM, Barwick K, et al. Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study. Ann Neurol. 2025;98(5):951–66.

5. Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. 2014;1(3):190–8.

6. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Current opinion in pharmacology. 2006;6(1):61–7.

7. Haneef Z, Matsumoto JH. Seizures and epilepsy syndromes. Epilepsy Fundamentals: A Concise Clinical Guide: Springer; 2025. p. 9–36.

8. Wirrell EC, Specchio N, Nabbout R, Pearl PL, Riney K. Epilepsy syndromes classification. Epilepsia Open. 2025.

9. Ngoh A, Clark M, Greenaway R, Chen X, Reid KM, Barwick K, et al. Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study. Annals of Neurology. 2025.

10. Avellaneda A, Sloan-Pena G, Bettridge C. B–17 Auditory-Verbal Regression in Landau-Kleffner Syndrome: A Review of Neuropsychological Patterns and Clinical Implications. Archives of Clinical Neuropsychology. 2025:acaf084. 169.

11. de Almeida Motta GC, Goes LS, de Aguiar PHSP, Santos FF, Pacheco CC, Franceschini PR, et al. landau-Kleffner syndrome: A systematic review and two illustrative cases. Revista Chilena de Neurocirugía. 2021;47(2):67–73.

12. Clark M, Holmes H, Ngoh A, Siyani V, Wilson G. Overview of Landau–Kleffner syndrome: early treatment, tailored education and therapy improve outcome. Paediatrics and Child Health. 2021;31(5):207–19.

13. Ahmed M, Saleem A, Nasir S, Ariff M, Iftikhar P. Landau-Kleffner syndrome: a diagnostic challenge. Cureus. 2020;12(3).

14. Ebrahim AK, Makhlooq JJ, Busehail MY. Landau–Kleffner Syndrome Can Herald the Diagnosis of GRIN2A Gene Mutation. Case Reports in Pediatrics. 2025;2025(1):8869587.

15. Ngoh A. Unravelling Molecular Genetic Causes and Disease Mechanisms in Landau Kleffner Syndrome: UCL (University College London); 2021.

16. Casella BB, de Brito Sampaio LP, Serafim A, Casella EB. Landau-Kleffner syndrome: The challenges of its treatment. Arquivos de Neuro-Psiquiatria. 2023;81(S 01):A107.

17. Moresco L, Bruschettini M, Calevo MG, Siri L. Pharmacological treatment for continuous spike‐wave during slow wave sleep syndrome and Landau‐Kleffner Syndrome. Cochrane Database of Systematic Reviews. 2020(11).

18. Samanta D. GRIN2A-related epilepsy and speech disorders: A comprehensive overview with a focus on the role of precision therapeutics. Epilepsy Research. 2023;189:107065.

19. Hausman-Kedem M, Menascu S, Greenstein Y, Fattal-Valevski A. Immunotherapy for GRIN2A and GRIN2D-related epileptic encephalopathy. Epilepsy Research. 2020;163:106325.

20. Kaga M. Treatment and Long-Term Prognosis. Landau-Kleffner Syndrome and Central Auditory Disorders in Children: Springer; 2021. p. 67–75.

  • Abstract Viewed: 2 times

Download Statastics

Developed By

Open Journal Systems